SPG(SH:600529) Sou Hu Cai Jing·2025-07-29 16:36Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. reported a slight decrease in total revenue for Q1 2025, while net profit showed a modest increase, indicating stable performance amidst market fluctuations [1]. Financial Performance - As of the end of Q1 2025, the company achieved total revenue of 1.242 billion RMB, a year-on-year decrease of 1.97% [1]. - The net profit attributable to shareholders was 224 million RMB, reflecting a year-on-year increase of 1.29% [1]. - The non-recurring net profit was 214 million RMB, with a year-on-year growth of 1.82% [1]. - Key financial ratios include a current ratio of 3.339, quick ratio of 2.552, and a debt-to-asset ratio of 19.10% [1]. Market Activity - The stock price closed at 23.21 RMB, with a slight increase of 0.22% [1]. - The trading volume was 140,700 lots, with a total transaction value of 325 million RMB [1]. - There was a net outflow of main funds amounting to 27.1472 million RMB, accounting for 8.36% of the transaction value [1]. - Large orders saw a net outflow of 22.1155 million RMB, representing 6.81% of the transaction value [1]. Company Overview - Shandong Pharmaceutical Glass Co., Ltd. was established in 1993 and is located in Zibo City, primarily engaged in the non-metallic mineral products industry [2]. - The company has a registered capital of 6.636 billion RMB and has made investments in 9 enterprises [2]. - The company has participated in 142 bidding projects and holds 33 trademark registrations and 613 patents, along with 184 administrative licenses [2].